Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Return on Sales (2016 - 2025)

Historic Return on Sales for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to 0.11%.

  • Heron Therapeutics' Return on Sales rose 300.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.1% for FY2024, which is 7800.0% up from last year.
  • Per Heron Therapeutics' latest filing, its Return on Sales stood at 0.11% for Q3 2025, which was up 300.0% from 0.04% recorded in Q2 2025.
  • Heron Therapeutics' 5-year Return on Sales high stood at 0.1% for Q4 2024, and its period low was 2.69% during Q2 2021.
  • Its 5-year average for Return on Sales is 1.1%, with a median of 0.79% in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Return on Sales crashed by -5300bps in 2021 and then surged by 19100bps in 2022.
  • Over the past 5 years, Heron Therapeutics' Return on Sales (Quarter) stood at 2.59% in 2021, then surged by 74bps to 0.68% in 2022, then soared by 56bps to 0.3% in 2023, then surged by 134bps to 0.1% in 2024, then crashed by -205bps to 0.11% in 2025.
  • Its Return on Sales was 0.11% in Q3 2025, compared to 0.04% in Q2 2025 and 0.08% in Q1 2025.